STOCK TITAN

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

Xenetic Biosciences (NASDAQ:XBIO) has announced that its collaboration partner, PeriNess, has entered into a Clinical Study Agreement for an exploratory clinical study of XBIO-015, a systemic DNase I candidate, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.

The study, to be conducted at Tel-Aviv Sourasky Medical Center, will primarily assess safety and tolerability of XBIO-015 in combination with relapsed chemotherapy regimens. Secondary objectives include evaluating efficacy through objective response rate and progression-free survival.

Research conducted at the center between 2013-2024 revealed that neutrophil extracellular traps (NETs) in pediatric sarcomas' tumor microenvironment is a prognostic factor, with higher NETs burden correlating to poor prognosis. XBIO-015, a recombinant DNase I enzyme, works by digesting these NETs.

This initiative follows Xenetic's December 2024 agreement with PeriNess for exploratory studies of recombinant DNase in pancreatic carcinoma and other solid tumors at Israeli medical centers.

Xenetic Biosciences (NASDAQ:XBIO) ha annunciato che il suo partner di collaborazione, PeriNess, ha stipulato un Accordo di Studio Clinico per uno studio clinico esplorativo su XBIO-015, un candidato DNase I sistemico, in pazienti con osteosarcoma recidivante/refrattario e sarcoma di Ewing.

Lo studio, che sarà condotto presso il Tel-Aviv Sourasky Medical Center, valuterà principalmente la sicurezza e la tollerabilità di XBIO-015 in combinazione con regimi chemioterapici recidivanti. Gli obiettivi secondari includono la valutazione dell'efficacia attraverso il tasso di risposta obiettivo e la sopravvivenza libera da progressione.

La ricerca condotta presso il centro tra il 2013 e il 2024 ha rivelato che le trappole extracellulari dei neutrofili (NETs) nel microambiente tumorale dei sarcomi pediatrici sono un fattore prognostico, con un carico maggiore di NETs che correlano a una prognosi sfavorevole. XBIO-015, un enzima ricombinante DNase I, agisce digerendo questi NETs.

Questa iniziativa segue l'accordo di Xenetic di dicembre 2024 con PeriNess per studi esplorativi di DNase ricombinante nel carcinoma pancreatico e in altri tumori solidi presso centri medici israeliani.

Xenetic Biosciences (NASDAQ:XBIO) ha anunciado que su socio de colaboración, PeriNess, ha firmado un Acuerdo de Estudio Clínico para un estudio clínico exploratorio de XBIO-015, un candidato DNase I sistémico, en pacientes con osteosarcoma refractario/recaída y sarcoma de Ewing.

El estudio, que se llevará a cabo en el Tel-Aviv Sourasky Medical Center, evaluará principalmente la seguridad y la tolerabilidad de XBIO-015 en combinación con regímenes de quimioterapia en recaída. Los objetivos secundarios incluyen evaluar la eficacia a través de la tasa de respuesta objetiva y la supervivencia libre de progresión.

La investigación realizada en el centro entre 2013 y 2024 reveló que las trampas extracelulares de neutrófilos (NETs) en el microambiente tumoral de los sarcomas pediátricos son un factor pronóstico, con una mayor carga de NETs que correlaciona con un mal pronóstico. XBIO-015, una enzima DNase I recombinante, actúa digiriendo estas NETs.

Esta iniciativa sigue al acuerdo de Xenetic en diciembre de 2024 con PeriNess para estudios exploratorios de DNase recombinante en carcinoma pancreático y otros tumores sólidos en centros médicos israelíes.

제넥틱 바이오사이언스 (NASDAQ:XBIO)는 협력 파트너인 페리네스가 XBIO-015의 탐색적 임상 연구를 위한 임상 연구 계약을 체결했다고 발표했습니다. 이 후보 물질은 재발성/내성 골육종 및 유잉 육종 환자를 대상으로 합니다.

이 연구는 텔아비브 소라스키 의료 센터에서 수행되며, 재발성 화학요법 요법과 병행한 XBIO-015의 안전성과 내약성을 주로 평가할 것입니다. 이차 목표는 객관적인 반응률과 무진행 생존율을 통해 효능을 평가하는 것입니다.

2013년부터 2024년까지 해당 센터에서 수행된 연구에서는 소아 육종의 종양 미세환경에서 호중구 세포외 그물(NETs)이 예후 인자라는 사실이 밝혀졌으며, NETs의 부담이 클수록 나쁜 예후와 연관이 있었습니다. XBIO-015는 이러한 NETs를 분해하는 재조합 DNase I 효소입니다.

이번 이니셔티브는 제넥틱이 2024년 12월 페리네스와 체결한 췌장암 및 기타 고형 종양에 대한 재조합 DNase의 탐색적 연구에 관한 계약을 따릅니다.

Xenetic Biosciences (NASDAQ:XBIO) a annoncé que son partenaire de collaboration, PeriNess, a signé un Accord d'Étude Clinique pour une étude clinique exploratoire sur XBIO-015, un candidat DNase I systémique, chez des patients atteints d'ostéosarcome récurrent/réfractaire et de sarcome d'Ewing.

L'étude, qui sera réalisée au Tel-Aviv Sourasky Medical Center, évaluera principalement la sécurité et la tolérabilité de XBIO-015 en combinaison avec des régimes de chimiothérapie récurrents. Les objectifs secondaires incluent l'évaluation de l'efficacité par le biais du taux de réponse objectif et de la survie sans progression.

Des recherches menées dans le centre entre 2013 et 2024 ont révélé que les pièges extracellulaires de neutrophiles (NETs) dans le microenvironnement tumoral des sarcomes pédiatriques constituent un facteur pronostique, une charge plus élevée de NETs étant corrélée à un mauvais pronostic. XBIO-015, une enzyme DNase I recombinante, agit en dégradant ces NETs.

Cette initiative fait suite à l'accord de Xenetic en décembre 2024 avec PeriNess pour des études exploratoires sur la DNase recombinante dans le carcinome pancréatique et d'autres tumeurs solides dans des centres médicaux israéliens.

Xenetic Biosciences (NASDAQ:XBIO) hat bekannt gegeben, dass sein Kooperationspartner PeriNess einen Klinischen Studienvertrag für eine explorative klinische Studie zu XBIO-015, einem systemischen DNase I-Kandidaten, mit Patienten, die an rezidivierenden/refraktären Osteosarkomen und Ewing-Sarkomen leiden, abgeschlossen hat.

Die Studie, die im Tel-Aviv Sourasky Medical Center durchgeführt wird, wird hauptsächlich die Sicherheit und Verträglichkeit von XBIO-015 in Kombination mit rezidivierenden Chemotherapie-Regimen bewerten. Sekundäre Ziele umfassen die Bewertung der Wirksamkeit anhand der objektiven Ansprechrate und der progressionsfreien Überlebenszeit.

Forschungen, die zwischen 2013 und 2024 in dem Zentrum durchgeführt wurden, haben ergeben, dass neutrophile extrazelluläre Fallen (NETs) im Tumormikroumfeld von pädiatrischen Sarkomen ein prognostischer Faktor sind, wobei eine höhere NET-Belastung mit einer schlechten Prognose korreliert. XBIO-015, ein rekombinantes DNase I-Enzym, wirkt, indem es diese NETs abbaut.

Diese Initiative folgt auf Xenetics Vereinbarung im Dezember 2024 mit PeriNess für explorative Studien zu rekombinanter DNase bei Pankreaskarzinom und anderen soliden Tumoren an israelischen medizinischen Zentren.

Positive
  • Expansion into new cancer treatment areas with high unmet medical need
  • Strong scientific rationale based on 11 years of research data
  • Multiple potential applications across various cancer types
  • Partnership with established medical center for clinical trials
Negative
  • Early-stage clinical trial with uncertain outcomes
  • Targeting aggressive cancers with historically poor treatment success
  • Complex combination therapy approach may increase risk of complications

Insights

Xenetic Biosciences' announcement represents measured clinical progress for their DNase platform through a strategically structured collaboration. Their partner PeriNess has secured a Clinical Study Agreement to evaluate XBIO-015 in relapsed/refractory osteosarcoma and Ewing sarcoma - aggressive pediatric cancers with 5-year survival rates of only 20-30%.

The scientific rationale appears sound, targeting neutrophil extracellular traps (NETs) in the tumor microenvironment. The company cites compelling preclinical evidence showing NETs as independent prognostic factors with clear association between NET burden and poor outcomes. Previous studies indicated elevated NET levels predicted poor chemotherapy response, relapse, and mortality.

This exploratory study will primarily assess safety and tolerability of XBIO-015 combined with chemotherapy, with secondary efficacy endpoints including objective response rate and progression-free survival. The inclusion of biomarker assessment adds translational value that could inform future development.

For context, this is part of Xenetic's broader strategy to conduct multiple exploratory studies across various combinations and indications, following their December 2024 agreement with PeriNess for similar studies in pancreatic and other solid tumors. For a micro-cap company ($5.2M), this collaborative approach enables clinical advancement with potentially shared resource burden, though specific financial terms weren't disclosed.

While this represents progress in Xenetic's development pipeline, investors should note this remains an early exploratory study that is still distant from potential commercialization.

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center

FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.

Prof. Ronit Elhasid, Director of Pediatric Hemato-Oncology and Bone Marrow Transplantation Department at the Dana-Dwek Children's Hospital in the Tel-Aviv Sourasky Medical Center ("Sourasky Center"), will act as the principal investigator and co-sponsor of the study along with the Health Corporation of the Tel Aviv Medical Center, an affiliate of the Sourasky Center.

"The primary objective of this study is to explore safety and tolerability in patients with relapsed/refractory osteosarcoma or Ewing sarcoma receiving XBIO-015 in combination with relapsed chemotherapy regimens. Secondary objectives include efficacy to be evaluated by the measure of objective response rate and progression-free survival. The study has a strong translational component with a complex assessment of biomarker response. Data on DNase I efficacy in combinations with chemotherapy in experimental models has encouraged us to support the study," stated Reid P. Bissonnette, Ph.D., Executive Consultant for Translational Research and Development of Xenetic.

Ewing sarcoma and osteosarcoma are aggressive orphan pediatric cancers that grow in bones or soft tissues. There is a lack of effective treatment options for children with recurrent and refractory disease where the five-year survival rate is only 20 to 30 percent. Studies conducted at Tel Aviv Sourasky Medical Center between 2013 and 2024 showed that the formation of neutrophil extracellular traps (NETs) in the tumor microenvironment of pediatric sarcomas is an independent prognostic factor, with a clear association between NETs burden and poor prognosis. According to the above research, elevated levels of NETs at diagnosis predicted a poor response to neoadjuvant chemotherapy, relapse, and death from the disease. Xenetic's proprietary recombinant DNase I is an enzyme that digests NETs in a tumor microenvironment.

James Parslow, Interim Chief Executive Officer and Chief Financial Officer of the Company stated, "As part of our overall development strategy, we aim to participate in a series of exploratory studies to evaluate XBI0-015 combinations with chemotherapy, radiotherapy and immunotherapy in various oncology indications. Our commitment to the DNase program remains steadfast and we are pleased to further expand our body of clinical data."

As previously announced, in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", and other words of similar meaning, including, but not limited to, all statements regarding expectations with respect to the Agreement, including statements regarding the proposed study under the Agreement to support an exploratory clinical study of our systemic DNase I candidate, XBIO-015, in patients with metastatic or relapsed osteosarcoma and Ewing sarcoma and the expected objectives of such study, and all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our overall development strategy, our commitment to the DNase program, our expectations regarding further expansion of our body of clinical data, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:

JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.



View the original press release on ACCESS Newswire

FAQ

What is the purpose of XBIO-015 clinical study for osteosarcoma and Ewing sarcoma?

The study aims to evaluate safety and tolerability of XBIO-015 combined with chemotherapy in relapsed/refractory cases, while measuring objective response rate and progression-free survival.

What is the current survival rate for relapsed osteosarcoma and Ewing sarcoma patients?

The five-year survival rate for children with recurrent and refractory disease is only 20 to 30 percent.

How does XBIO-015 work in treating sarcomas?

XBIO-015 is a recombinant DNase I enzyme that digests neutrophil extracellular traps (NETs) in the tumor microenvironment, which are associated with poor prognosis.

What were the findings of Tel Aviv Sourasky Medical Center's research on NETs in sarcomas?

Studies from 2013-2024 showed elevated NETs levels at diagnosis predicted poor response to chemotherapy, relapse, and death from the disease.

What other cancer types is XBIO investigating for DNase treatment?

XBIO is exploring DNase treatment for pancreatic carcinoma and other locally advanced or metastatic solid tumors in combination with chemotherapy and immunotherapy.
Xenetic Biosciences Inc

NASDAQ:XBIO

XBIO Rankings

XBIO Latest News

XBIO Stock Data

3.90M
1.25M
19.06%
6.44%
0.54%
Biotechnology
Pharmaceutical Preparations
Link
United States
FRAMINGHAM